A biopharmaceutical company, primarily engaged in the discovery and development of a new therapeutic class of drugs for the treatment of cancer and other pathological conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
History will be made. New cancer drug finishing successful Phase III trials, hopefully will get FDA approval before end of 2008.
Low float, no gaps to fill, just successfully tested the 200 day moving average.
I have to note that with the last press release last week ACEL had only THREE more deaths to go before being able to close their phase III study and begin to submit to the FDA. With the last conference call thay were hoping to submit by end of April. When this pops it will go very fast, I have been a believer in Onconase and recent studies are finally documenting it's invaluable use for a variety of cancers. Onconase may very well be a magic bullet for cancer treatments due to it's novel (and propietary) attacking of bad cells and keeping good cells alone (no more chemo folks!). If phase III shows Onocanase prolongs life 3 or more months ...huge success...huge pop.